Gland Pharma Limited delivered exceptional financial results for Q4 FY26, with consolidated net profit surging 97% year-on-year to ₹3.7 billion and revenue reaching a record ₹17,428 million, up 22% YoY. The company's EBITDA climbed 48% to ₹5.1 billion with margin expanding to 29.43% from 24.39% in the same period last year. For the full year FY26, consolidated revenue rose 14.50% to ₹64,307 million, supported by 36% CDMO growth, strong US and Europe performance, and Cenexi revenue of €182 million. The company's base business delivered strong results with gross profit margin at 62% and adjusted EBITDA margin of 41% in Q4 FY26.
Shares of Gland Pharmaceuticals Ltd. experienced significant momentum on Monday, rallying as much as 13% in trading. According to reports from NDTV Profit, the stock was trading at ₹2,098, representing gains of around 12.2% compared to Friday's closing price of ₹1,868. The positive market reaction was driven by the company's impressive fourth quarter financial performance, with the stock showing strong performance across multiple timeframes including +13.69% in 1 day, +11.53% in 5 days, +21.18% in 1 month, +16.07% in 6 months, and +45.45% over 1 year.
The company's global presence showed strong performance across key markets. The US market remained the largest contributor, accounting for 53% of group revenues in FY26, with Q4 FY26 revenues of ₹9,807 million (24% YoY growth). Europe contributed 22% with Q4 FY26 revenues of ₹3,814 million (36% YoY growth), supported by strong Cenexi momentum including the ramp-up of inactivated vaccine and sterile ophthalmic gel. Rest of the World contributed 17% with Q4 FY26 revenues of ₹2,549 million (6% YoY growth), driven by key products including Huminsulin and Rocuronium Bromide. Other Core Markets (Canada, Australia, and New Zealand) accounted for 4% with Q4 FY26 revenues of ₹588 million (-2% YoY).
The company's CDMO business demonstrated exceptional growth, contributing 46% of consolidated revenues in Q4 FY26 with 36% year-on-year growth. Key product launches included Dalbavancin and Brimonidine in the US market alongside uptake in base business products such as Micafungin, Rocuronium Bromide, and Daptomycin. Cenexi, Gland Pharma's European CDMO subsidiary, reported revenue of €45 million (₹4,780 million) in Q4 FY26, with full-year FY26 revenue standing at €182 million (₹18,693 million), up 25% year-on-year in rupee terms. The company launched 31 products in the US during FY26, including five in Q4 FY26 alone, with cumulative US ANDA filings reaching 388 (337 approved, 51 pending).
Looking ahead, Gland Pharma has provided optimistic guidance for future growth. The company expects FY27 revenue growth at 12-13%, driven by launches and CDMO projects. Growth is anticipated to accelerate to around 15% in FY28 and 19-20% in FY29. The company has also guided margins to sustain at a consolidated level of 25-25%, with base business margins being guided at 33-35%. The Board of Directors has recommended a final dividend of ₹20 per equity share (face value of ₹1 each), representing 2000%, for FY26, subject to shareholder approval at the 48th Annual General Meeting scheduled for Tuesday, August 25, 2026. The record date for determining eligibility is Tuesday, August 11, 2026.
